References
- ShamloulRGhanemHErectile dysfunctionLancet2013381986115316523040455
- BraunMWassmerGKlotzTReifenrathBMathersMEngelmannUEpidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’Int J Impot Res200012630531111416833
- LewisRWFugl-MeyerKSCoronaGDefinitions/epidemiology/risk factors for sexual dysfunctionJ Sex Med201074 Pt 21598160720388160
- AraujoABTravisonTGGanzPErectile dysfunction and mortalityJ Sex Med2009692445245419538544
- FeldmanHAGoldsteinIHatzichristouDGKraneRJMcKinlayJBImpotence and its medical and psychosocial correlates: results of the Massachusetts male aging studyJ Urol1994151154618254833
- BaconCGMittlemanMAKawachiIGiovannucciEGlasserDBRimmEBSexual function in men older than 50 years of age: results from the health professionals follow-up studyAnn Intern Med2003139316116812899583
- LatiniDMPensonDFLubeckDPWallaceKLHenningJMLueTFLongitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the exploratory comprehensive evaluation of erectile dysfunction studyJ Urol200316941437144212629379
- MontagueDKJarowJPBroderickGAThe management of erectile dysfunction: an AUA updateJ Urol2005174123023915947645
- CarvalheiraAAPereiraNMMarocoJForjazVDropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuationJ Sex Med2012992361236922616766
- SchwartzBGKlonerRADrug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertensionCirculation20101221889520606131
- LueTFErectile dysfunctionN Engl J Med2000342241802181310853004
- Saenz de TejadaIMolecular mechanisms for the regulation of penile smooth muscle contractilityInt J Impot Res200214Suppl 1S6S1011850728
- MontorsiFBrigantiASaloniaAErectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery diseaseEur Urol200344336036412932937
- NehraAJacksonGMinerMThe Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular diseaseMayo Clin Proc201287876677822862865
- InmanBASauverJLJacobsonDJA population-based, longitudinal study of erectile dysfunction and future coronary artery diseaseMayo Clin Proc200984210811319181643
- MehrotraNGuptaMKovarAMeibohmBThe role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapyInt J Impot Res200719325326416988721
- PryorJLRedmonBNew therapies and delivery mechanisms for treatment of erectile dysfunctionInt J Impot Res200012Suppl 4S158S16211035406
- GiulianoFAmarEChevallierDMontaigneOJoubertJMChartier-KastlerEHow urologists manage erectile dysfunction after radical prostatectomy: a national survey (REPAIR) by the French urological associationJ Sex Med20085244845718042217
- LeaAPBrysonHMBalfourJAIntracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunctionDrugs Aging19968156748785470
- HeatonJPLordingDLiuSNIntracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic menInt J Impot Res200113631732111918246
- LinetOIOgrincFGEfficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study GroupN Engl J Med1996334148738778596569
- ManciniMRainaRAgarwalANervaFColpiGMSildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled studyInt J Impot Res200416181214963465
- ShabsighRPadma-NathanHGittlemanMMcMurrayJKaufmanJGoldsteinIIntracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra)Urology200055447748010736486
- Garrido AbadPSinues OjasBMartinez BlazquezLConde CaturlaPFernandez ArjonaMSafety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitorsActas Urol Esp2015391063564026049734
- YiouRCuninPde la TailleASexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomyJ Sex Med20118257558220807323
- YiouREbrahiminiaVMouracadePLingombetOAbbouCSexual quality of life in women partnered with men using intracavernous alprostadil injections after radical prostatectomyJ Sex Med20131051355136223444881
- PorstHThe rationale for prostaglandin E1 in erectile failure: a survey of worldwide experienceJ Urol199615538028158583582
- LakinMMMontagueDKVanderBrug MedendorpSTesarLSchoverLRIntracavernous injection therapy: analysis of results and complicationsJ Urol19901436113811412342174
- HanchanaleVEardleyIAlprostadil for the treatment of impotenceExpert Opin Pharmacother201415342142824369066
- Padma-NathanHHellstromWJKaiserFETreatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study GroupN Engl J Med19973361178970933
- PorstHTransurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil – a comparative study in 103 patients with erectile dysfunctionInt J Impot Res1997941871929442415
- KimSCAhnTYChoiHKMulticenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in KoreaInt J Impot Res20001229710111052635
- BecherETopical alprostadil cream for the treatment of erectile dysfunctionExpert Opin Pharmacother20045362363215013930
- WolkaAMRyttingJHReedBLFinninBCThe interaction of the penetration enhancer DDAIP with a phospholipid model membraneInt J Pharm20042711–251015129968
- YeagerJBeihnRMRetention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunctionInt J Impot Res2005171919515538395
- McVaryKTPolepalleSRiggiSPelhamRWTopical prostaglandin E1 SEPA gel for the treatment of erectile dysfunctionJ Urol19991623 Pt 172673010458353
- GoldsteinIPaytonTRSchechterPJA double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunctionUrology200157230130511182341
- Padma-NathanHSteidleCSalemSTayseNYeagerJHarningRThe efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe EDInt J Impot Res2003151101712605235
- SteidleCPadma-NathanHSalemSTopical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II programUrology20026061077108212475674
- Padma-NathanHYeagerJLAn integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patientsUrology200668238639116904458
- Padma-NathanHMcMurrayJGPullmanWEOn-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunctionInt J Impot Res20011312911313831
- AndersonPCGommersallLHayneDAryaMPatelHRNew phosphodiesterase inhibitors in the treatment of erectile dysfunctionExpert Opin Pharmacother20045112241224915500370
- YoungJMVardenafilExpert Opin Investig Drugs2002111014871496
- RooneyMPfisterWMahoneyMNelsonMYeagerJSteidleCLong-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunctionJ Sex Med20096252053419138370